Nucleoside Supplementation for Post-Infection Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and clotting/thrombotic disorders post-infection, such as those caused by COVID-19 and other pathogens, are inadequate due to the depletion of nucleosides and nucleotides, particularly guanosine and its derivatives, leading to symptoms like brain fog, fatigue, and clotting issues.
Innovation Solution
Administering a nucleoside and/or nucleotide formulation, including guanosine, orally, enterally, or parenterally, to supplement the body's pool of nucleosides and nucleotides, thereby preventing or treating post-pathogenic infection neurological and clotting/thrombotic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If infectious agents replicate using host nucleotides, then the pathogen can multiply and cause infection, but the host's nucleoside and nucleotide pools become depleted leading to neurological and clotting disorders
Solution Approach 1:
The patent applies preliminary action by administering nucleoside and nucleotide supplements (particularly guanosine) to patients before or during infection to pre-establish adequate pools of these substances. This proactive supplementation prevents the depletion that would otherwise occur during pathogen replication, thereby preventing neurological and clotting disorders before they manifest.
2Reliability
If the body supplements nucleosides and nucleotides during infection, then neurological and clotting disorders can be prevented or treated, but the pathogen may have increased availability of building blocks for replication
Solution Approach 1:
The patent applies parameter changes by specifically targeting and supplementing guanosine and related nucleosides/nucleotides that are depleted during infection. Rather than providing a broad spectrum of nutrients that would benefit pathogen replication, the invention focuses on restoring specific host pools that are consumed during the immune response and pathogen metabolism, thereby improving host reliability without significantly aiding pathogen productivity.
3Reliability
If high doses of nucleosides and nucleotides are administered to treat post-infection neurological disorders, then symptoms such as brain fog and fatigue can be mitigated, but the complexity of dosing and administration increases
Solution Approach 1:
The patent applies self-service by utilizing the body's existing metabolic pathways for nucleoside and nucleotide synthesis and utilization. The supplemented guanosine and related compounds are processed through natural cellular mechanisms already present in the host, eliminating the need for complex external delivery systems or sophisticated dosing regimens. The body's own metabolic machinery handles the distribution and utilization of these substances.
Data Source
AI summary
Compositions and methods for the prevention and treatment of signs and symptoms of post-viral neurologic disorders, such as those that occur in COVID 19.